Developer docs
API playgroundTry for free, no card

Search company profiles

Ori Biotech

Full company profile

uuid0000863

Namestring
Ori Biotech
Legal namestring
Oribiotech Limited
Websiteurl
oribiotech.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Ori Biotech is a private UK-headquartered cell and gene therapy (CGT) manufacturing technology company that has developed the IRO® platform, a fully closed and automated system that integrates proprietary hardware, consumables, and software to transition cell therapy manufacturing seamlessly from R&D to GMP production. The core platform centers on a novel bellows bioreactor (50ml to 1L operating volume achieving up to 12B cells and ~170x fold expansion) and the patented OriConnect™ sterile fluid transfer system, combined with 21 CFR Part 11-compliant flexible software and a cloud-native architecture for remote monitoring and process optimization. The company targets four horizontal customer segments: cell and gene therapy developers, contract development and manufacturing organizations (CDMOs), academic medical centers, and large pharmaceutical companies. Ori generated its first clinical patient dose in May 2026 through a partnership with ImmuXell in China and holds one of the first FDA Advanced Manufacturing Technology (AMT) designations awarded since the program launched in 2024.

Ori Biotech sells the IRO platform and its consumables through direct enterprise sales and a Preferred Partner Network that includes Charles River Laboratories, CTMC, ElevateBio, Kincell Bio, MaxCyte, and Fresenius Kabi, among others. Revenue is generated via quote-based, multi-year platform contracts with no publicly disclosed pricing, though the company claims IRO reduces manufacturing costs by 30-50%, labor costs by 50-70%, and enables operation in GMP Grade C/D cleanrooms versus the Grade A/B required by legacy manual systems. The company is backed by institutional investors including Novalis LifeSciences (which led the $100M+ Series B in January 2022), Delin Ventures, and Northpond Ventures, and is governed by a board chaired by Dr. Annalisa Jenkins with Non-Executive Directors Tony Hunt and Henrik Andersen. Headquartered in London with North American operations in Philadelphia, Ori holds 207 patents globally and operates across North America, Europe, China, and Australia through 18-22 active partners as of mid-2026.

Short descriptiontext

Ori Biotech develops the IRO® platform, a fully closed and automated manufacturing system that integrates hardware, consumables, and software to scale cell and gene therapies from R&D to GMP. It sells to therapy developers, CDMOs, academic medical centers, and large pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, gene therapy automation, bioreactor technology, CGT manufacturing platform, bioprocessing consumables
Industry4 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Industrial Instruments For Measurement, Display, And Control3823
Product category
Cell and Gene Therapy Manufacturing Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1IRO® Platform Sales
TypeHardware Sales
Description

Ori Biotech generates revenue through the sale and deployment of its IRO® manufacturing platform, which includes proprietary hardware instruments, consumables, and associated software. The platform is sold to cell and gene therapy developers, CDMOs, academic medical centers, and large pharmaceutical companies for use in research, process development, and GMP manufacturing.

oribiotech.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise platform sale - IRO platform sold directly to therapy developers, CDMOs, and pharma companies for CGT manufacturing
ModelOtherBilling cadenceMulti-year contract
Notes

Platform includes hardware instruments, consumables ( bioreactor, OriConnect), and software. Quote-based pricing with multi-year commercial relationships typical for CGT manufacturing technology.

oribiotech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1IRO
Description

Next-generation automated cell and gene therapy manufacturing platform that automates better biology, accelerates development, and scales from R&D to GMP.

oribiotech.com
Core offering1 text field

Ori Biotech develops and sells the IRO® Platform, a fully closed, automated manufacturing system for cell and gene therapies that integrates proprietary hardware (the IRO instrument), single-use consumables (including the patented OriConnect™ sterile fluid transfer system and the Novel Bellows Bioreactor with 50ml–1L operating range), and a flexible, 21 CFR Part 11 compliant software layer. The platform enables therapy developers, CDMOs, academic medical centers, and large pharma companies to run activation, transduction, and expansion in a single consumable, transitioning seamlessly from R&D to GMP manufacturing in lower-grade (C/D) cleanrooms while reducing manufacturing costs by 30–50% and labor costs by 50–70%.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • Up to 3.5x higher transduced cell yield vs control systems
+8 more records
Product overview1 text field

Ori Biotech offers the IRO® platform as its core unified product—a next-generation, fully closed, automated manufacturing system for cell and gene therapies. The platform integrates proprietary hardware (the IRO instrument with Novel Bellows Bioreactor), consumables (including the patented OriConnect™ System for sterile fluid transfer), and flexible software for process control and monitoring. The system enables seamless transition from R&D to GMP manufacturing on a single platform. Supporting the core platform, Ori provides the Ori Data Hub (with internal and partner data, case studies, and application notes), the Patient Access Tracker (tracking commercial cell therapy patient access), and the Ori Spotlight Podcast (industry insights). The platform was commercially launched in December 2024 and holds FDA Advanced Manufacturing Technology designation.

Product and service3 records
1IRO® Platform
CategoryCell and gene therapy manufacturing platform
Description

A next-generation, fully closed, automated manufacturing platform for cell and gene therapies that integrates proprietary hardware, consumables, software, data, and analytics. The platform enables seamless transition from R&D to GMP manufacturing on a single system, increasing throughput, improving quality, and reducing costs for cell and gene therapy developers, CDMOs, AMCs, and pharmaceutical companies.

2OriConnect™ System
CategorySterile fluid transfer consumable
Description

A patented closed and automated sterile fluid transfer technology consumable for the IRO® platform. It enables aseptic processing and eliminates the need for manual tube welding during the cell therapy manufacturing process, minimizing dead volumes and reducing the risk of human error.

3Novel Bellows Bioreactor
CategorySingle-use bioreactor consumable
Description

A wide operating volume bioreactor (50ml to 1L) consumable for the IRO® platform with an adjustable mixing mechanism supporting static, rocking, and compression modes. The flexible operating volume range allows activation, transduction, and expansion in one consumable, supporting up to 12B cells at ~170x fold expansion.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

MoU signed April 2026 to bring IRO platform to Australia and Asia Pacific. Goals include deploying IRO at CTPL for process development and clinical manufacturing; optimizing AdAlta's cellular immunotherapy pipeline for scalability and cost. Collaboration targets 10-50x higher throughput, shorter manufacturing times, 30-50% cost savings. Supports AdAlta's 'East to West' globalization strategy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Strategic partnership formed December 2025. First patient dosed in May 2026 in investigator-initiated trial using ImmuXell's TCR-T cell therapy for solid tumors (KRAS G12V mutations including colorectal, pancreatic, and lung cancers). IRO platform deployed at ImmuXell's Shanghai facilities. First Ori Biotech collaboration in Asia Pacific. Partnership validates IRO platform as GMP-compatible manufacturing solution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Partnership to evaluate IRO platform in support of advancing CGT research and clinical development. SCRI contributed to development of Breyanzi. 13th partner actively using IRO platform. Evaluating how early adoption of automation can accelerate product development, drive enhanced consistency, and enable scalable manufacturing.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-11
Description

Collaboration aimed at enhancing manufacturing efficiencies and expanding adoption of autologous cellular therapies. Integration of MaxCyte's ExPERT electroporation system with Ori's IRO platform for improved cell therapy manufacturing workflows.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-18
Description

PPN includes Charles River Laboratories, CTMC (joint venture between Resilience and MD Anderson), ElevateBio, Kincell Bio, other leading CDMOs, and two Tier 1 pharma companies. Network accelerates commercialization of cell and gene therapies through collaborative deployment of IRO platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-12-10
Description

Collaboration to advance modular, scalable manufacturing of cell and gene therapies. Integration of platforms to address manufacturing challenges and enable distributed manufacturing for therapy developers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closest direct competitor - develops automated cell therapy manufacturing platforms (Cell Shuttle). Raised $612M and competes head-to-head with Ori's IRO for the same cell therapy developer, CDMO, and pharma customers.

TypeBroad incumbent
Description

Global bioprocessing incumbent with broad cell therapy workflow solutions (including Sefia, Xuri, and cell expansion systems). Competes with Ori at the broader workflow level rather than as a purpose-built CGT platform; Ori's CTO Stuart Milne previously led R&D teams at Cytiva's predecessor (Asymptote/GE Healthcare).

TypeDirect peer
Description

Offers the Prodigy and MACS platforms for automated cell processing and manufacturing, directly competing with IRO in the cell therapy manufacturing automation space, particularly for CAR-T and similar autologous therapies.

TypeBroad incumbent
Description

Major life sciences tools and bioprocessing supplier (Gibco CTS, CTS Rotea counterflow centrifugation system) overlapping with IRO's customer base. Ori's board director Paul Meister is former Thermo Fisher Chairman.

TypeBroad incumbent
Description

World's largest CDMO with extensive cell and gene therapy manufacturing services and bioprocessing tools. Competes as both a customer (via Ori partners like Minaris) and indirectly as an integrated platform provider.

TypeEmerging player
Description

Provider of electroporation technology (ExPERT platform) for cell engineering with strategic integration partnership with Ori. Former CFO Amanda Murphy is now an Ori advisor. Adjacent rather than head-to-head competitor.

TypeOthers
Description

Global healthcare company with cell therapy manufacturing solutions (Cellvite/CABALETTE) partnered with Ori for integration. Adjacent rather than direct competitor.

TypeBroad incumbent
Description

Major bioprocessing equipment manufacturer offering bioreactors and cell processing platforms. Ori's Hardware Associate Director Mark Varley previously held roles at Sartorius Stedim Biotech.

TypeEmerging player
Description

Supplies biopreservation and cold chain solutions for cell therapies; complementary rather than competing with IRO platform, but serves the same CGT manufacturing customer base. Ori strategic advisor Mike Rice is former BioLife CEO.

TypeOthers
Description

Major CDMO and CGT manufacturer that is also an Ori Preferred Partner Network member and customer. More a partner/customer than direct competitor, but could develop competing internal platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles39 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ori Biotech

Cell and Gene Therapy Manufacturing Platformoribiotech.com

Ori Biotech develops the IRO® platform, a fully closed and automated manufacturing system that integrates hardware, consumables, and software to scale cell and gene therapies from R&D to GMP. It sells to therapy developers, CDMOs, academic medical centers, and large pharma.

What Ori Biotech does

Ori Biotech is a private UK-headquartered cell and gene therapy (CGT) manufacturing technology company that has developed the IRO® platform, a fully closed and automated system that integrates proprietary hardware, consumables, and software to transition cell therapy manufacturing seamlessly from R&D to GMP production. The core platform centers on a novel bellows bioreactor (50ml to 1L operating volume achieving up to 12B cells and ~170x fold expansion) and the patented OriConnect™ sterile fluid transfer system, combined with 21 CFR Part 11-compliant flexible software and a cloud-native architecture for remote monitoring and process optimization. The company targets four horizontal customer segments: cell and gene therapy developers, contract development and manufacturing organizations (CDMOs), academic medical centers, and large pharmaceutical companies. Ori generated its first clinical patient dose in May 2026 through a partnership with ImmuXell in China and holds one of the first FDA Advanced Manufacturing Technology (AMT) designations awarded since the program launched in 2024.

Ori Biotech sells the IRO platform and its consumables through direct enterprise sales and a Preferred Partner Network that includes Charles River Laboratories, CTMC, ElevateBio, Kincell Bio, MaxCyte, and Fresenius Kabi, among others. Revenue is generated via quote-based, multi-year platform contracts with no publicly disclosed pricing, though the company claims IRO reduces manufacturing costs by 30-50%, labor costs by 50-70%, and enables operation in GMP Grade C/D cleanrooms versus the Grade A/B required by legacy manual systems. The company is backed by institutional investors including Novalis LifeSciences (which led the $100M+ Series B in January 2022), Delin Ventures, and Northpond Ventures, and is governed by a board chaired by Dr. Annalisa Jenkins with Non-Executive Directors Tony Hunt and Henrik Andersen. Headquartered in London with North American operations in Philadelphia, Ori holds 207 patents globally and operates across North America, Europe, China, and Australia through 18-22 active partners as of mid-2026.

Ori Biotech firmographics

Firmographics
Name
Ori Biotech
Legal name
Oribiotech Limited
Website
https://oribiotech.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Ori Biotech develops the IRO® platform, a fully closed and automated manufacturing system that integrates hardware, consumables, and software to scale cell and gene therapies from R&D to GMP. It sells to therapy developers, CDMOs, academic medical centers, and large pharma.
Ownership category
akta.pro rank

Ori Biotech industry classification

Industry
Product category
Cell and Gene Therapy Manufacturing Platform
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Industrial Instruments For Measurement, Display, And Control (3823)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)

Keywords

  • Cell therapy manufacturing
  • Gene therapy automation
  • Bioreactor technology
  • CGT manufacturing platform
  • Bioprocessing consumables

Where Ori Biotech is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Ori Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. IRO® Platform Sales: Ori Biotech generates revenue through the sale and deployment of its IRO® manufacturing platform, which includes proprietary hardware instruments, consumables, and associated software. The platform is sold to cell and gene therapy developers, CDMOs, academic medical centers, and large pharmaceutical companies for use in research, process development, and GMP manufacturing.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise platform sale - IRO platform sold directly to therapy developers, CDMOs, and pharma companies for CGT manufacturing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Ori Biotech product offering

Product offering

Core offering

Ori Biotech develops and sells the IRO® Platform, a fully closed, automated manufacturing system for cell and gene therapies that integrates proprietary hardware (the IRO instrument), single-use consumables (including the patented OriConnect™ sterile fluid transfer system and the Novel Bellows Bioreactor with 50ml–1L operating range), and a flexible, 21 CFR Part 11 compliant software layer. The platform enables therapy developers, CDMOs, academic medical centers, and large pharma companies to run activation, transduction, and expansion in a single consumable, transitioning seamlessly from R&D to GMP manufacturing in lower-grade (C/D) cleanrooms while reducing manufacturing costs by 30–50% and labor costs by 50–70%.

Product overview

Ori Biotech offers the IRO® platform as its core unified product—a next-generation, fully closed, automated manufacturing system for cell and gene therapies. The platform integrates proprietary hardware (the IRO instrument with Novel Bellows Bioreactor), consumables (including the patented OriConnect™ System for sterile fluid transfer), and flexible software for process control and monitoring. The system enables seamless transition from R&D to GMP manufacturing on a single platform. Supporting the core platform, Ori provides the Ori Data Hub (with internal and partner data, case studies, and application notes), the Patient Access Tracker (tracking commercial cell therapy patient access), and the Ori Spotlight Podcast (industry insights). The platform was commercially launched in December 2024 and holds FDA Advanced Manufacturing Technology designation.

Differentiator

Problem solved

Functional benefit

Brands

  • IRO: Next-generation automated cell and gene therapy manufacturing platform that automates better biology, accelerates development, and scales from R&D to GMP.

Products and services

  • IRO® Platform A next-generation, fully closed, automated manufacturing platform for cell and gene therapies that integrates proprietary hardware, consumables, software, data, and analytics. The platform enables seamless transition from R&D to GMP manufacturing on a single system, increasing throughput, improving quality, and reducing costs for cell and gene therapy developers, CDMOs, AMCs, and pharmaceutical companies.
  • OriConnect™ System A patented closed and automated sterile fluid transfer technology consumable for the IRO® platform. It enables aseptic processing and eliminates the need for manual tube welding during the cell therapy manufacturing process, minimizing dead volumes and reducing the risk of human error.
  • Novel Bellows Bioreactor A wide operating volume bioreactor (50ml to 1L) consumable for the IRO® platform with an adjustable mixing mechanism supporting static, rocking, and compression modes. The flexible operating volume range allows activation, transduction, and expansion in one consumable, supporting up to 12B cells at ~170x fold expansion.

Quantifiable outcome

  • Up to 3.5x higher transduced cell yield vs control systems
  • +8 more outcomes

Companies that use Ori Biotech

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Ori Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature5 records

Ori Biotech partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • AdAlta and Cell Therapies Pty LtdcoreStrategic or Co-development Partner · 21 April 2026MoU signed April 2026 to bring IRO platform to Australia and Asia Pacific. Goals include deploying IRO at CTPL for process development and clinical manufacturing; optimizing AdAlta's cellular immunotherapy pipeline for scalability and cost. Collaboration targets 10-50x higher throughput, shorter manufacturing times, 30-50% cost savings. Supports AdAlta's 'East to West' globalization strategy.
  • ImmuXell BiotechcoreStrategic or Co-development Partner · 1 December 2025Strategic partnership formed December 2025. First patient dosed in May 2026 in investigator-initiated trial using ImmuXell's TCR-T cell therapy for solid tumors (KRAS G12V mutations including colorectal, pancreatic, and lung cancers). IRO platform deployed at ImmuXell's Shanghai facilities. First Ori Biotech collaboration in Asia Pacific. Partnership validates IRO platform as GMP-compatible manufacturing solution.
  • Seattle Children's Research InstitutecoreStrategic or Co-development Partner · 11 November 2025Partnership to evaluate IRO platform in support of advancing CGT research and clinical development. SCRI contributed to development of Breyanzi. 13th partner actively using IRO platform. Evaluating how early adoption of automation can accelerate product development, drive enhanced consistency, and enable scalable manufacturing.
  • MaxCytecoreTechnology or Integration · 11 June 2025Collaboration aimed at enhancing manufacturing efficiencies and expanding adoption of autologous cellular therapies. Integration of MaxCyte's ExPERT electroporation system with Ori's IRO platform for improved cell therapy manufacturing workflows.
  • Preferred Partner Network (PPN) MemberscoreChannel Partner/ Reseller/ Distributor · 18 March 2025PPN includes Charles River Laboratories, CTMC (joint venture between Resilience and MD Anderson), ElevateBio, Kincell Bio, other leading CDMOs, and two Tier 1 pharma companies. Network accelerates commercialization of cell and gene therapies through collaborative deployment of IRO platform.
  • Fresenius KabicoreTechnology or Integration · 10 December 2024Collaboration to advance modular, scalable manufacturing of cell and gene therapies. Integration of platforms to address manufacturing challenges and enable distributed manufacturing for therapy developers.

Scale indicators19 records

Recent moves6 records

Expansion highlights6 records

Ori Biotech competitors and assessment

Company assessment

Direct peers

  • Cellares: Closest direct competitor - develops automated cell therapy manufacturing platforms (Cell Shuttle). Raised $612M and competes head-to-head with Ori's IRO for the same cell therapy developer, CDMO, and pharma customers.
  • Miltenyi Biotec: Offers the Prodigy and MACS platforms for automated cell processing and manufacturing, directly competing with IRO in the cell therapy manufacturing automation space, particularly for CAR-T and similar autologous therapies.

Broad incumbents

  • Cytiva (Danaher): Global bioprocessing incumbent with broad cell therapy workflow solutions (including Sefia, Xuri, and cell expansion systems). Competes with Ori at the broader workflow level rather than as a purpose-built CGT platform; Ori's CTO Stuart Milne previously led R&D teams at Cytiva's predecessor (Asymptote/GE Healthcare).
  • Thermo Fisher Scientific: Major life sciences tools and bioprocessing supplier (Gibco CTS, CTS Rotea counterflow centrifugation system) overlapping with IRO's customer base. Ori's board director Paul Meister is former Thermo Fisher Chairman.
  • Lonza Group: World's largest CDMO with extensive cell and gene therapy manufacturing services and bioprocessing tools. Competes as both a customer (via Ori partners like Minaris) and indirectly as an integrated platform provider.
  • Sartorius AG: Major bioprocessing equipment manufacturer offering bioreactors and cell processing platforms. Ori's Hardware Associate Director Mark Varley previously held roles at Sartorius Stedim Biotech.

Emerging players

  • MaxCyte: Provider of electroporation technology (ExPERT platform) for cell engineering with strategic integration partnership with Ori. Former CFO Amanda Murphy is now an Ori advisor. Adjacent rather than head-to-head competitor.
  • BioLife Solutions: Supplies biopreservation and cold chain solutions for cell therapies; complementary rather than competing with IRO platform, but serves the same CGT manufacturing customer base. Ori strategic advisor Mike Rice is former BioLife CEO.

Others

  • Fresenius Kabi: Global healthcare company with cell therapy manufacturing solutions (Cellvite/CABALETTE) partnered with Ori for integration. Adjacent rather than direct competitor.
  • Charles River Laboratories: Major CDMO and CGT manufacturer that is also an Ori Preferred Partner Network member and customer. More a partner/customer than direct competitor, but could develop competing internal platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Ori Biotech social profiles

Digital presence

Ori Biotech compliance and trust

Trust signal

Compliance3 records

Ori Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ori Biotech leadership team

Management profile

Number of profiles

Profiles39 records

Ori Biotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ori Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ori Biotech

What does Ori Biotech do?

Ori Biotech develops and sells the IRO® Platform, a fully closed, automated manufacturing system for cell and gene therapies that integrates proprietary hardware (the IRO instrument), single-use consumables (including the patented OriConnect™ sterile fluid transfer system and the Novel Bellows Bioreactor with 50ml–1L operating range), and a flexible, 21 CFR Part 11 compliant software layer. The platform enables therapy developers, CDMOs, academic medical centers, and large pharma companies to run activation, transduction, and expansion in a single consumable, transitioning seamlessly from R&D to GMP manufacturing in lower-grade (C/D) cleanrooms while reducing manufacturing costs by 30–50% and labor costs by 50–70%.

Is Ori Biotech a public or private company?

Ori Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ori Biotech founded?

Ori Biotech was founded in 2018. It employs 51 to 100 people.

Where is Ori Biotech based?

Ori Biotech is headquartered in London, United Kingdom, in the Europe region.

How does Ori Biotech make money?

One revenue line is on record: IRO® Platform Sales.

Who are Ori Biotech's main competitors?

Direct peers on record are Cellares and Miltenyi Biotec. Broad incumbents are Cytiva (Danaher), Thermo Fisher Scientific, Lonza Group and Sartorius AG. Emerging players are MaxCyte and BioLife Solutions. Others are Fresenius Kabi and Charles River Laboratories.

Does Ori Biotech have an API?

No public API is recorded for Ori Biotech.

What industry is Ori Biotech in?

Ori Biotech's product category is Cell and Gene Therapy Manufacturing Platform. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAAJAE, Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES). Its NAICS code is 3345 and its SIC code is 3823.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deOribiotech Ltd.: Ori Biotech gibt eine 10-jährige Partnerschaft im Wert von 120 Mio. US-Dollar zur Förderung der automatisierten Herstellung kommerzieller Zelltherapien bekanntOri Biotech announced a 10-year partnership with an unnamed biopharmaceutical company to integrate its IRO platform into a commercial cell therapy manufacturing process. The deal is valued at up to $120 million, covering services, milestone payments, and equipment purchases. The partnership aims to modernize the partner's production infrastructure for autologous cell therapies.BioProcess InternationalOri unveils CGT platform to combat manufacturing challengesOri Biotech has launched its IRO platform, an automated system designed to streamline cell and gene therapy manufacturing by reducing labor costs and processing times. The company plans to install the first commercial units at customer sites in early 2025 and aims to support its first partner clinical trial that same year.BioSpaceOri Biotech and ImmuXell Announce Strategic Partnership and Dose First PatientOri Biotech and ImmuXell Biotech announced a strategic partnership formed in December 2025, under which the first patient was dosed in an investigator-initiated trial using ImmuXell's TCR-T cell therapy for KRAS G12V-mutant solid tumors, manufactured on Ori's IRO® platform. The IRO® system was deployed and optimized at ImmuXell's Shanghai facilities in four months, and the companies plan to file an IND application in China for a Phase 1 clinical trial later in 2026. The partnership marks Ori Biotech's first collaboration in the Asia-Pacific region and validates the IRO® platform as a GMP-compatible manufacturing solution for cell therapies.Business Wire BlogOri Biotech and ImmuXell Announce Strategic Partnership and Dose First PatientOri Biotech and ImmuXell Biotech announced their strategic partnership began in December 2025, marking the milestone of the first patient dosed in an investigator-initiated trial using ImmuXell's TCR-T cell therapy manufactured on Ori's IRO® platform. The trial targets solid tumors with KRAS G12V mutations, including colorectal, pancreatic, and lung cancers. The IRO® platform was deployed at ImmuXell's Shanghai facilities, achieving first patient dosing within four months of installation, with the companies planning to file an IND application in China for a Phase 1 clinical trial later in 2026.Coherent Market InsightsCell Therapy Manufacturing Platform Market Size, 2026-2033The global cell therapy manufacturing platform market is valued at USD 6,538.8 million in 2026 and projected to reach USD 13,667.5 million by 2033, growing at a 15.2% CAGR, driven by rising demand for autologous and allogeneic cell therapies and the shift toward automated, closed-system GMP manufacturing. Key recent developments include Cellares raising USD 257 million in Series D funding and securing a USD 380 million global manufacturing agreement with Bristol Myers Squibb, while Ori Biotech received U.S. FDA Advanced Manufacturing Technology designation for its IRO platform. Regulatory support from the U.S. FDA, EMA, and PMDA is accelerating approvals and GMP compliance infrastructure, with North America leading at 35.8% market share and Asia Pacific emerging as the fastest-growing region at 28.3%.BioSpaceOpinion: Automated Manufacturing Will Meet CAR T DemandCellares COO Idan Ostfeld argues in an opinion piece that next-generation automation is essential to meet growing demand for CAR T cell therapies, stating that manual labor currently accounts for 50% of cell therapy manufacturing costs. Cellares received the first-ever FDA Advanced Manufacturing Technologies (AMT) designation for its Cell Shuttle automated manufacturing system, with Ori Biotech and Cellino subsequently receiving the same designation. The author, who previously led commercialization of Novartis' Kymriah and Johnson & Johnson/Legend Biotech's Carvykti, contends that U.S. policy shifts including the BIOSECURE Act and FDA's AMT program are pushing the cell and gene therapy field toward automated, standardized, and domestically anchored production.SynBioBetaOri Biotech's IRO® Platform Earns FDA Advanced Manufacturing Technology DesignationOri Biotech announced that its IRO® platform has received Advanced Manufacturing Technology (AMT) designation from the FDA, making it one of the first technologies to achieve this recognition since the program launched in 2024. The fully closed system automates, digitizes, and standardizes cell and gene therapy manufacturing, offering reduced costs, increased throughput, decreased batch failures, and accelerated development timelines. The designation provides Ori Biotech's partners with earlier and more frequent regulatory engagement throughout the IND, NDA, and BLA processes, facilitating a more streamlined path from early-stage development to commercial launch.BioSpaceAs CGT Struggles To Scale, FDA’s New Designation Could Smooth Post-Approval PivotsExperts report that the FDA’s Advanced Manufacturing Technologies designation could help improve production processes for approved cell and gene therapies, addressing supply chain and manufacturing challenges faced by biotechs. Several companies, including Cellares, Cellino, and Oribiotech, have received the first AMT awards, which could facilitate post-approval manufacturing changes. The designation aims to support companies in making regulatory-approved process modifications to enhance commercial viability.OribiotechOri Biotech Partners with Seattle Children's Research Institute to Advance Cell Therapy ManufacturingOri Biotech announced a partnership with Seattle Children’s Research Institute to evaluate its IRO platform for advancing cell and gene therapy manufacturing. This collaboration marks the 13th active partner for the platform, which recently received FDA Advanced Manufacturing Technology designation to support scalable and consistent production.